$VRTX

Vertex Among 3 Stocks Considered Below Estimated Fair Value

Vertex, ESCO, and Tutor Perini are highlighted as undervalued stocks based on cash flow analysis. Vertex (market cap $2.31B) trades at $14.23, 49% below estimated fair value. ESCO (market cap $7.18B) trades at $276.96, 13.8% below fair value. Tutor Perini (market cap $4.67B) trades at $88.84, 40.2% below fair value. All show strong earnings growth but face varying challenges.

Original reporting
Published Aug 31, 2026, 5:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 5:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$VRTX
Neutral
low confidence
Mentioned
$VRTX · $TPC
Relevance
4/10
AlphAI data visualization · based on simplywall.st
Decision brief

The 30-second read

$VRTXNeutralLow
01

Why it matters

Provides no new corporate disclosures; serves as a thematic value suggestion.

02

Market read

Valuation commentary may influence value‑focused investors but lacks actionable new information.

03

What to watch

Potential debt burden and one‑off items could limit upside.

Relevance 4/10Novelty 2/10Timing: none

Background

The article presents a Simply Wall St valuation roundup of three U.S. stocks deemed undervalued.

Company-level read

Ticker impact

$VRTXNeutralLow confidence
Context

Vertex is highlighted as trading 49% below its estimated fair value based on cash‑flow analysis.

Expected impact

Modest upside if market re‑prices the discount.

Evidence & confidence

No new corporate event; only a valuation opinion.

$TPCNeutralLow confidence
Context

Tutor Perini is described as 40.2% below fair value after reporting higher net income and contract wins.

Expected impact

Small upside potential if market acknowledges earnings momentum.

Evidence & confidence

Information is a re‑statement of known results, not a new event.

Market effects

Highlights potential undervaluation in software, aerospace, and construction sectors.

U.S. market focus; no broader regional effect.

Limited to investors tracking U.S. value opportunities.

Counterpoint

Valuation gaps may reflect underlying risks not captured in cash‑flow models.

Key entities

  • Vertex, Inc.

    Enterprise tax technology provider.

  • ESCO Technologies Inc.

    Aerospace and defense components supplier.

  • Tutor Perini Corporation

    Construction and engineering firm.

Related articles

$VRTXHighAI 8/10

Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?

Vertex Pharmaceuticals (VRTX) shares have risen 13% year-to-date but have pulled back 8% from their 52-week high. Q2 revenue grew 12% to $3.33B, with EPS up 8% to $4.31. The company raised full-year revenue guidance to $13.1B-$13.2B. Key catalysts include label expansion for Casgevy, potential approval for povetacicept, and Phase 2 trials for inaxaplin. Vertex's CF business remains strong with no significant competition.

$TPCMedAI 8/10

Tutor Perini's $334M Cash Flow Sets a Record: Can Momentum Last?

Tutor Perini reported record operating cash flow of $334.1M in H1 2026, up 17% YoY. Revenues rose 19% to $1.64B, with a $19.9B backlog. Cash reserves increased to $423.5M. Management expects 2026 cash flow to be second-best annually. TPC stock is up 27% YTD, with a forward P/E of 14.13. Earnings estimates for 2026 and 2027 were revised upwards.

$VRTXMed

Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis

Vertex Pharmaceuticals (VRTX) highlighted its pipeline advancements, including potential treatments for kidney diseases, pain management, and endocrine disorders. The company expects interim analysis for inaxaplin in Q1 2027 and a PDUFA date for povetacicept in IgAN by Nov. 30, 2026. Vertex also reported progress in its pain franchise, JOURNAVX, and the acquisition of Crinetics Pharmaceuticals, with peak sales potential of $5 billion for PALSONIFY and atumelnant.

$VRTXHighAI 9/10

Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis

Vertex Pharmaceuticals (VRTX) acquired Crinetics for $10B, gaining Palsonify, an approved acromegaly treatment, and atumelnant, a CAH drug in Phase 3. Citigroup expects Palsonify to generate $700M in annual sales by 2030, with atumelnant adding upside. The deal diversifies Vertex's revenue beyond cystic fibrosis but carries execution risks.